BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16941685)

  • 1. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.
    Niro GA; Ciancio A; Gaeta GB; Smedile A; Marrone A; Olivero A; Stanzione M; David E; Brancaccio G; Fontana R; Perri F; Andriulli A; Rizzetto M
    Hepatology; 2006 Sep; 44(3):713-20. PubMed ID: 16941685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
    Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
    Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
    Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
    Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis.
    Gunsar F; Akarca US; Ersoz G; Kobak AC; Karasu Z; Yuce G; Ilter T; Batur Y
    Antivir Ther; 2005; 10(6):721-6. PubMed ID: 16218171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon plus adefovir versus either drug alone for hepatitis delta.
    Wedemeyer H; Yurdaydìn C; Dalekos GN; Erhardt A; Çakaloğlu Y; Değertekin H; Gürel S; Zeuzem S; Zachou K; Bozkaya H; Koch A; Bock T; Dienes HP; Manns MP;
    N Engl J Med; 2011 Jan; 364(4):322-31. PubMed ID: 21268724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response.
    Karaca C; Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydin E; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S
    Antivir Ther; 2013; 18(4):561-6. PubMed ID: 22976528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight-based dosing regimen of peg-interferon α-2b for chronic hepatitis delta: a multicenter Romanian trial.
    Gheorghe L; Iacob S; Simionov I; Vadan R; Constantinescu I; Caruntu F; Sporea I; Grigorescu M
    J Gastrointestin Liver Dis; 2011 Dec; 20(4):377-82. PubMed ID: 22187703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience.
    Abbas Z; Memon MS; Mithani H; Jafri W; Hamid S
    Antivir Ther; 2014; 19(5):463-8. PubMed ID: 24423484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis.
    Abdrakhman A; Ashimkhanova A; Almawi WY
    Antiviral Res; 2021 Jan; 185():104995. PubMed ID: 33321155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy.
    Nadeem A; Hussain MM; Aslam M; Hussain T; Butt IF; Ali Khan S; Asad A
    J Ayub Med Coll Abbottabad; 2009; 21(2):103-6. PubMed ID: 20524482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b.
    Erhardt A; Gerlich W; Starke C; Wend U; Donner A; Sagir A; Heintges T; Häussinger D
    Liver Int; 2006 Sep; 26(7):805-10. PubMed ID: 16911462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
    Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
    Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
    Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
    Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
    Kamal SM; El Tawil AA; Nakano T; He Q; Rasenack J; Hakam SA; Saleh WA; Ismail A; Aziz AA; Madwar MA
    Gut; 2005 Jun; 54(6):858-66. PubMed ID: 15888797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
    Hasan F; Al-Khaldi J; Asker H; Al-Ajmi M; Owayed S; Varghese R; Siddique I; Al-Nakib B
    Antivir Ther; 2004 Aug; 9(4):499-503. PubMed ID: 15456080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients.
    el-Zayadi A; Selim O; Haddad S; Simmonds P; Hamdy H; Badran HM; Shawky S
    Ital J Gastroenterol Hepatol; 1999; 31(6):472-5. PubMed ID: 10575565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial.
    Canbakan B; Senturk H; Tabak F; Akdogan M; Tahan V; Mert A; Sut N; Ozaras R; Midilli K; Ozbay G
    J Gastroenterol Hepatol; 2006 Apr; 21(4):657-63. PubMed ID: 16677149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.